MICHAEL JIROUSEK, Ph.D.
Chief Operating Officer
Michael is the Chief Operating Officer of Frequency Therapeutics. Prior to Frequency, he co-founded Catabasis Pharmaceuticals and served as Chief Scientific Officer, where his contributions helped create several potential new therapeutics and guide the company to an IPO in 2015. During his almost 30-year career, Michael has overseen 100’s of R&D programs and has brought more than 15 new therapeutics from discovery into clinical study to address muscular dystrophy, dyslipidemia, cancer and a variety of metabolic diseases. Michael is the former Senior Vice President of Research for Sirtris Pharmaceuticals, acquired by GlaxoSmithKline in 2008 after an IPO in 2007. He also led the metabolic disease therapeutic area at Pfizer’s Laboratories in La Jolla, California and has had leadership roles at Abbott Laboratories and Eli Lilly. Michael holds a Ph.D. in Chemistry from Case Western Reserve University and completed his post-doctoral study at Harvard University.